tiprankstipranks
Trending News
More News >
Keymed Biosciences, Inc. (HK:2162)
:2162
Hong Kong Market

Keymed Biosciences, Inc. (2162) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

Keymed Biosciences, Inc. has a market cap or net worth of HK$11.48B. The enterprise value is HK$6.84B.
Market CapHK$11.48B
Enterprise ValueHK$6.84B

Share Statistics

Keymed Biosciences, Inc. has 279.74M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding279.74M
Owned by Insiders
Owned by Instutions

Financial Efficiency

Keymed Biosciences, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per EmployeeHK$75,626.789
Profits Per Employee-HK$752,170.906
Employee Count1,258
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of Keymed Biosciences, Inc. is ―. Keymed Biosciences, Inc.’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, Keymed Biosciences, Inc. had revenue of HK$95.14M and earned -HK$946.23M in profits. Earnings per share was -HK$3.63.
RevenueHK$95.14M
Gross ProfitHK$58.61M
Operating Income-HK$1.05B
Pretax Income-HK$937.02M
Net Income-HK$946.23M
EBITDA-961.64M
Earnings Per Share (EPS)-3.63

Cash Flow

In the last 12 months, operating cash flow was -HK$880.81M and capital expenditures -HK$223.40M, giving a free cash flow of -HK$1.10B billion.
Operating Cash Flow-HK$880.81M
Free Cash Flow-HK$1.10B
Free Cash Flow per Share-HK$3.95

Dividends & Yields

Keymed Biosciences, Inc. pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.39
52-Week Price Change42.37%
50-Day Moving Average36.99
200-Day Moving Average36.22
Relative Strength Index (RSI)73.45
Average Volume (3m)2.50M

Important Dates

Keymed Biosciences, Inc. upcoming earnings date is Sep 2, 2025, TBA.
Last Earnings DateMar 24, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date

Financial Position

Keymed Biosciences, Inc. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, Keymed Biosciences, Inc. has paid HK$8.47M in taxes.
Income TaxHK$8.47M
Effective Tax Rate

Enterprise Valuation

Keymed Biosciences, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

Keymed Biosciences, Inc. has HK$2.58B in cash and marketable securities with HK$751.34M in debt, giving a net cash position of -HK$1.83B billion.
Cash & Marketable SecuritiesHK$2.58B
Total DebtHK$751.34M
Net Cash-HK$1.83B
Net Cash Per Share-HK$6.53
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for Keymed Biosciences, Inc. is HK$60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$60.00
Price Target Upside36.83%
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score6
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis